Change of manufacturer for topical erectile dysfunction drug

Vitaros (alprostadil) is an option for patients with conditions that preclude them from using oral erectile dysfunction treatments.
Vitaros (alprostadil) is an option for patients with conditions that preclude them from using oral erectile dysfunction treatments.

The erectile dysfunction treatment Vitaros (alprostadil) is now available from Ferring.

Originally launched in 2014 by Takeda, the topical cream incorporates a skin-permeation enhancer that aids absorption of alprostadil through the glans of the penis. After application, the onset of action is within five to 30 minutes and the effect lasts for 1-2 hours after dosing.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases